FDA warned Strategia Project Management that its microSURE Hand Sanitizer is an unapproved, misbranded drug marketed with COVID-19 claims.
What happened
FDA reviewed the company's websites and social media on September 28, 2021, and found the non-alcohol microSURE Hand Sanitizer offered for sale with claims it can mitigate, prevent, treat, diagnose, or cure COVID-19 and other serious infections. FDA said the product contains benzalkonium chloride and website claims describe silica dioxide as active, but the product does not conform to the applicable proposed over-the-counter antiseptic standards.
What FDA found
The hand sanitizer is an unapproved new drug because it lacks FDA approval and is not generally recognized as safe and effective for its labeled use.
FD&C Act section 505(a), 21 U.S.C. 355(a)The product is misbranded because it is a nonprescription drug that does not meet the requirements for marketing without an approved application.
FD&C Act sections 502(a) and (ee), 21 U.S.C. 352(a) and (ee)Website claims that the product eradicates viruses including SARS-CoV-2, MERS, and SARS establish that it is intended to prevent or treat disease.
FD&C Act section 201(g)(1)(B), 21 U.S.C. 321(g)(1)(B); 21 CFR 201.128The website presents silica dioxide as an active ingredient, but it is not a permitted active ingredient for consumer antiseptic hand rubs under the applicable standards.
21 CFR 201.66(b)(2); 1994 TFM as amended by the 2016 Consumer Antiseptic Rubs Proposed RuleThe product does not conform to the FDA's proposed over-the-counter antiseptic standards, so it is not eligible for marketing without an approved application under section 505G.
FD&C Act section 505G(a)(3), 21 U.S.C. 355h(a)(3)Introducing the product into interstate commerce is prohibited because it is an unapproved and misbranded drug.
FD&C Act sections 301(a) and 301(d), 21 U.S.C. 331(a) and (d)
What FDA wants
FDA tells the company to immediately stop selling the products for COVID-19 or other unapproved uses and, within 48 hours, email FDA with the specific corrective steps, documentation, and a plan to prevent recurrence. If it cannot complete action in 48 hours, it must explain the delay and give a completion time.
Who should pay attention
- retailers and online marketplaces selling microSURE Hand Sanitizer
- hand sanitizer brands making antiviral or COVID-19 claims
- consumers using non-alcohol antiseptics advertised for COVID-19
This is a summary. Read the original letter on fda.gov.